Colorectal Study, Too
You Gotta Be Kidney? AVEO, Astellas Trying Tivo in Breast
By Randy Osborne
Monday, December 3, 2012
As investors continue to digest news regarding FDA concerns about overall survival trends of renal cell carcinoma patients in a Phase III trial with tivozanib, AVEO Oncology Inc. and Astellas Pharma Inc. have begun a Phase II study with the compound in triple-negative breast cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.